Pfizer launched its investigational oral Janus Kinase 3 (JAK3) inhibitor PF-06651600, which is used for the treatment of patients with alopecia areata.
Alopecia areata is chronic autoimmune skin disease in which immune cells attack healthy hair follicles, causing hair loss in round patches and causes hair loss on the scalp, face, or body.
The mean age for the disease’s onset is between 25 and 35 years, but the disease also affects children and adolescents irrespective of sex or ethnicity.
JAK3 inhibitor PF-06651600 can be used to address these critical unmet needs.
The JAK Pathways play a key role in inflammatory processes as they are involved in signaling for over 50 cytokines and growth factors, many of which drive immune-mediated conditions.
JAK inhibition offers the potential for new advanced treatment options for these conditions through unique and targeted selectivity.
These inhibitors have the potential of meeting significant unmet needs in multiple inflammatory conditions.
PF-06651600 is an oral small molecule that selectivity inhibits Janus Kinase (JAK) 3.5.
The drug is under investigation for its use in the treatment of alopecia areata, rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.
Pfizer has established a leading kinase research capability with multiple unique kinase inhibitor therapies in development.
FDA has granted a breakthrough therapy designation to its investigational drug PF-06651600 for the treatment of patients with alopecia areata based on the data from the company’s Phase 2 study.
Apart from PF-06651600, Pfizer has other kinase inhibitors undergoing trials for various indications. These include PF-04965842, PF-06700841, PF-06650833, and PF-06826647.
